Clinical Responses and Transcriptomic Analysis of Spesolimab in a Girl With Severe Dermatitis, Multiple Allergies and Metabolic Wasting Syndrome

Authors:

Abstract
Severe dermatitis, multiple allergies, and metabolic wasting syndrome (SAM) is a rare inherited disorder caused by biallelic loss‐of‐function mutations in the desmoglein‐1 (DSG1) or desmoplakin (DSP) genes. Previous studies have demonstrated that acitretin and systemic biologics targeting IL‐17, IL‐12/IL‐23, and IL‐4 are effective in treating SAM syndrome. We report the case of an 8‐year‐old girl diagnosed with SAM syndrome who suffered from recurrent rash episodes due to infections and achieved remission with a combination therapy of Spesolimab and acitretin. Comprehensive diagnostic workup, including serum inflammatory factor assays, flow cytometry, skin immunohistochemical staining, and skin RNA sequencing (RNA‐seq), revealed elevated IL‐36G levels in SAM syndrome, which may be associated with the pathogenesis of generalised pustular psoriasis (GPP) through shared IL‐36‐mediated mechanisms. This case highlights the therapeutic potential of targeting the IL‐36 pathway in SAM syndrome and supports the use of skin RNA‐seq for personalised selection of anti‐inflammatory biologics in rare dermatological disorders. This report marks the first clinical application of Spesolimab in SAM syndrome, offering a novel therapeutic approach.
Funding Information
  • National Natural Science Foundation of China

This publication has 16 references indexed in Scilit: